US Stock MarketDetailed Quotes
HRTX Heron Therapeutics
- 1.070
- +0.010+0.94%
Close Nov 22 16:00 ET
- 1.100
- +0.030+2.80%
Post 20:01 ET
162.74MMarket Cap-6687P/E (TTM)
1.100High1.060Low1.34MVolume1.080Open1.060Pre Close1.45MTurnover1.16%Turnover RatioLossP/E (Static)152.09MShares3.93052wk High-4.07P/B123.05MFloat Cap1.04052wk Low--Dividend TTM115.00MShs Float830.000Historical High--Div YieldTTM3.77%Amplitude0.500Historical Low1.080Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Heron Therapeutics Stock Forum
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time
- The VAN is expected to launch in Q4 2024
SAN DIEGO, Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced tha...
1 min ago
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle ("Van")
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...
No comment yet